The risk-based monitoring (RBM) and central statistical monitoring solution provider has added two new hires to its US commercial team and over the next 12 months will increase its staff by 50%.
“CluePoints is seeing demand from both the biopharma and medical device sponsor communities, as well as contract research organizations,” Steve Young, Chief Operations Officer at CluePoints told Outsourcing-Pharma.com.
“Demand for CluePoints is being driven by a combination of factors, including the need to ensure compliance with regulations, the desire for an optimal RBM-enabling technology platform, and also in response to the FDA’s use of this statistical approach to interrogate submission data and select sites for inspection based on the results,” Young said.
The location enables CluePoints to serve its customer base in the US Northeast/Mid-Atlantic regions, and enables it to more effectively support customers across North America, Young explained.
“We expect the US headquarters to grow in the next five years and to see CluePoints opening other facilities to ensure that we are working in close partnership with customers to further enhance the software product,” he said.
“The CluePoints roadmap in terms of technology innovation and resource growth is extremely strong and we anticipate that this type of enabling technology will revolutionize how clinical trials are managed in future.”